Results 11 to 20 of about 23,621 (250)
Phosphorylation of Tyr188 in the WW domain of YAP1 plays an essential role in YAP1-induced cellular transformation [PDF]
Cell Cycle, 2016 The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell fate and tumorigenesis. The pivotal effector of this pathway is YAP1, a transcriptional co-activator amplified in mouse and human cancers where it promotes epithelial-to-mesenchymal transition (EMT) and malignant transformation.
Ying-Wei, Li +12 more
openaire +3 more sources
Journal of Translational Medicine, 2023 Abstract Background Gallbladder cancer (GBC) is the most prevalent and invasive biliary tract malignancy. As a GTPase-activating protein, Neurofibromin 1 (NF1) is a tumor suppressor that negatively regulates the RAS signaling pathway, and its abnormality leads to neurofibromatosis type 1 (NF-1) disease. However, the role
Lingxiao Zhang +9 more
openaire +4 more sources
Requirement for YAP1 signaling in myxoid liposarcoma [PDF]
EMBO Molecular Medicine, 2019 Myxoid liposarcomas (MLS), malignant tumors of adipocyte origin, are driven by the FUS-DDIT3 fusion gene encoding an aberrant transcription factor. The mechanisms whereby FUS-DDIT3 mediates sarcomagenesis are incompletely understood, and strategies to selectively target MLS cells remain elusive.
Marcel Trautmann +23 more
openaire +5 more sources
Interhemispheric Pediatric Meningioma, YAP1 Fusion-Positive [PDF]
Diagnostics, 2022 Meningiomas are uncommon in children and usually arise in the context of tumor-predisposing syndromes. Recently, YAP1-fusions have been identified for the first time as potential NF2-independent oncogenic drivers in the development of meningiomas in pediatric patients.
Silvia Esposito +13 more
openaire +4 more sources
USP24 promotes hepatocellular carcinoma progression by deubiquitinating and stabilizing YAP1
Cancer Cell InternationalYes-associated protein 1 (YAP1) plays a pivotal role in promoting the progression of hepatocellular carcinoma (HCC). Emerging evidence shows that inducing YAP1 degradation represents a promising strategy.
Huizhuang Shan +11 more
doaj +2 more sources
Cell Cycle, 2010 Comment on: Hamilton G, et al. ATM regulates a RASSF1A-dependent DNA damage response. Curr Biol 2009; 19:2020-5.
Yee, K, O'Neill, E
openaire +2 more sources
Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma [PDF]
Journal of Clinical Investigation, 2019 Poroma is a benign skin tumor exhibiting terminal sweat gland duct differentiation. The present study aimed to explore the potential role of gene fusions in the tumorigenesis of poromas. RNA sequencing and reverse transcription PCR identified highly recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poromas (92/104 lesions, 88.5%) and their rare malignant ...
Shigeki Sekine +13 more
openaire +2 more sources
Yap1-2 Isoform Is the Primary Mediator in TGF-β1 Induced EMT in Pancreatic Cancer
Frontiers in Oncology, 2021 Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive human malignancy and intrinsically resistant to conventional therapies. YAP1, as a key downstream effector of the Hippo pathway, plays an important role in tumorigenesis including PDAC ...
Chao Gao +14 more
doaj +1 more source
CircSETD2 inhibits YAP1 by interaction with HuR during breast cancer progression
Cancer Biology & Therapy, 2023 CircRNAs have been proven to play a pivotal role in cancer progression. The present study aims to explore the roles and related mechanisms of circSETD2 in breast cancer proliferation, migration and invasion. The expression of circSETD2 in BC was assessed
Lan Jing +4 more
doaj +1 more source
YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers. [PDF]
PLoS Genetics, 2015 YAP1 is a major effector of the Hippo pathway and a well-established oncogene. Elevated YAP1 activity due to mutations in Hippo pathway components or YAP1 amplification is observed in several types of human cancers.
Claudia Stein +10 more
doaj +1 more source